

# Iodine-131-SPET/CT and <sup>18</sup>F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma

**Yan-Hong Xu<sup>1,2</sup> MD,**  
**Chen-Tian Shen<sup>1</sup> MD,**  
**Yan-Li Xue<sup>1</sup> MD,**  
**Zhong-Ling Qiu<sup>1</sup> MD,**  
**Quan-Yong Luo<sup>1</sup> MD**

1. Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China  
 2. Department of Radiology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China

\*\*\*

**Keywords:** <sup>131</sup>I-SPET/CT  
<sup>18</sup>F-FDG PET/CT  
 - Mediastinal lymph node metastases  
 - Differentiated thyroid carcinoma

## Correspondence address:

Quan-Yong Luo MD Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, 600 Yishan Rd., Shanghai, 200233, China, E-mail: lqyn@sh163.net  
 Tel: 86-21-64369181  
 Fax: 86-21-64701361

Received:

2 August 2013

Accepted revised:

31 October 2013

## Abstract

Mediastinal lymph node metastases (MLNM) from differentiated thyroid carcinoma (DTC) are considered difficult to diagnose. The aim of this study was to assess the value of iodine-131 (<sup>131</sup>I) single photon emission tomography/computed tomography (SPET/CT) and of <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) for the diagnosis of MLNM from DTC. Five hundred and eleven consecutive patients operated for DTC and treated with <sup>131</sup>I for ablation of the remnant thyroid and/or for treatment of metastases were enrolled in the study and underwent an <sup>131</sup>I whole body scan (<sup>131</sup>I-WBS). Thirty seven sites of increased <sup>131</sup>I uptake, on the <sup>131</sup>I-WBS that could be an indication for MLNM were re-evaluated by a <sup>131</sup>I-SPET/CT scan. Thirty four other patients with negative <sup>131</sup>I-WBS but having elevated serum thyroglobulin (Tg), were examined by <sup>18</sup>F-FDG PET/CT to possibly diagnose MLNM. A total of 44 DTC patients with MLNM were identified, among the above 37 and 34 cases: 25/37 (67.6%) cases were examined and identified by <sup>131</sup>I-SPET/CT and 19/34 (55.9%) cases by <sup>18</sup>F-FDG PET/CT. A total of 25 and 19 cases were identified. The male-to-female ratio and the average age in patients with <sup>18</sup>F-FDG-avid MLNM were significantly higher than in patients with <sup>131</sup>I-avid MLNM. Among the above 44 patients, 40 patients had superior mediastinal nodal metastases, 9 had aortic nodal metastases and only 1 inferior mediastinal nodal metastases. A patient could have metastases in more than one site. In conclusion, our study suggests that in 511 operated DTC patients, treated for remnant ablation and/or for metastases and examined by <sup>131</sup>I-WBS, there were 37 cases doubtful of having MLNM in the <sup>131</sup>I-WBS and 34 cases doubtful, because of negative <sup>131</sup>I-WBS and elevated Tg. The <sup>131</sup>I-SPET/CT scan was sensitive for detecting MLNM in 25 of the 37 cases and the <sup>18</sup>F-FDG PET/CT in 19 of the 34 cases. These hybrid imaging modalities, when applied as above, were suitable for detecting more MLNM and thus, better supporting treatment planning in these DTC patients.

*Hell J Nud Med* 2013; 16(3): 199-203

Published on line: 28 November 2013